Fintech Ramp's valuation hits $16 billion in deal led by Peter Thiel's Founders Fund
Ramp, which offers a financial operations platforms to corporate clients, has raised its valuation to $16 billion in a new fundraising led by long-time investor Founders Fund, Peter Thiel's venture firm.
The $200 million round is the fifth that Founders' has led for Ramp and raised its valuation by $3 billion. It last raised money at a $13 billion valuation in March.
Founded in 2019, Ramp offers services that cover corporate cards, procurement, bookkeeping, travel booking, and vendor management, and says it handles tens of billions in purchases annually across 40,000 companies.
Ramp ranked No. 6 on the 2025 CNBC Disruptor 50 list.
Its list of clients includes CBRE, Shopify and two fellow 2025 CNBC Disruptor 50 companies, Anduril and Notion (Founders Fund is also an investor in Anduril).
Ramp has been increasing its offerings for enterprise companies. In January, it launched Ramp Treasury, which allows companies to earn 2.5% on idle operating cash. It also acquired Venue, an AI-powered procurement software startup, and used it to roll out new vendor payment tools. Last June, it debuted Ramp Travel, partnering with Priceline for booking and managing expenses for corporate travel, moving into the market of fellow Disruptor Navan.
The company says it has shipped 270 features this year, with a focus on increased automation of financial operations and use of AI, and still serves only 1.5% of the addressable U.S. market.
Ramp co-founder and CEO Eric Glyman wrote in a blog post about the fundraising that he is guided by his favorite companies' missions: "Increase the GDP of the internet (ten-time Disruptor Stripe); Make humanity a multiplanetary species (SpaceX); Be Earth's most customer-obsessed company (Amazon)."
"Ours can fit on a Post-it too," he wrote. "Save your company time and money (without you noticing)."
"Let the robots chase receipts and close your books, so you can use your brain and build things," he added.
Additional investors in the round included Thrive Capital, D1 Capital Partners, General Catalyst, GIC, ICONIQ Growth, Khosla Ventures, Sands Capital, 8VC, Lux Capital, Stripes, 137 Ventures, Avenir Growth, and Definition Capital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
VERSES® Announces Consolidation of Class A Subordinate Voting Shares
VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSD) ('VERSES'' or the 'Company'), a cognitive computing company specializing in next-generation agentic software systems, announces the Company is consolidating all of its issued and outstanding Class A Subordinate Voting Shares (the 'Subordinate Voting Shares') on the basis of one (1) post-consolidated Subordinate Voting Share for every three (3) pre-consolidated Subordinate Voting Shares held (the 'Consolidation'). The Company's stock symbol will change to VRSSD following the Consolidation. The Company's board of directors approved the Consolidation on June 10, 2025. Trading of the Subordinate Voting Shares on a post-Consolidation basis on Cboe Canada Inc. ('Cboe') is expected to commence on or about June 23, 2025. The new CUSIP number for the Subordinate Voting Shares will be 92539Q604 and the new ISIN number will be CA92539Q6040. As of the date hereof, the Company currently has 26,239,469 Subordinate Voting Shares issued and outstanding. The Consolidation will reduce the number of outstanding Subordinate Voting Shares to approximately 8,746,490 Subordinate Voting Shares issued and outstanding. Holders of physical share certificates of the Company are required to complete and return a letter of transmittal to the Company's transfer agent, Endeavor Trust Corporation, in order to receive their post-Consolidation Subordinate Voting Shares. Please visit for guidance on the process for returning your pre-consolidation share certificates and receiving your post-Consolidation Subordinate Voting Shares. Shareholders whose shares are represented by a direct registration system statement will automatically receive their post-Consolidation Subordinate Voting Shares without any further action. Shareholders who hold their shares through an intermediary are encouraged to contact their intermediaries if they have any questions. No fractional Subordinate Voting Shares will be issued under the Consolidation as fractional Subordinate Voting Shares will be rounded either up or down to the nearest whole number of Subordinate Voting Shares. The exercise price and number of Subordinate Voting Shares issuable pursuant to the exercise of any outstanding convertible securities, including incentive stock options and warrants, will also be adjusted in accordance with the Consolidation ratio. About VERSES VERSES® is a cognitive computing company building next-generation intelligent software systems modeled after the wisdom and genius of Nature. Designed around first principles found in science, physics and biology, our flagship product, Genius,™ is an agentic enterprise intelligence platform designed to generate reliable domain-specific predictions and decisions under uncertainty. Imagine a Smarter World that elevates human potential through technology inspired by Nature. Learn more at , LinkedIn and X . On behalf of the Company Gabriel René, Founder & CEO, VERSES AI Inc. Press Inquiries: press@ Investor Relations Inquiries James Christodoulou, Chief Financial Officer IR@ , +1(212)970-8889 Cautionary Note Regarding Forward-Looking Statements This news release contains statements which constitute 'forward-looking information' or 'forward-looking statements' within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and plans of the Company. Forward-looking information and forward-looking statements are often identified by the words 'may', 'would', 'could', 'should', 'will', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' or similar expressions. More particularly and without limitation, this news release contains forward–looking statements and information relating to the expectation that the Company will complete the Consolidation; the effective date of the Consolidation; the number of Subordinate Voting Shares outstanding following the Consolidation; the treatment of fractional shares in the Consolidation; and other statements that are not historical facts. The forward–looking statements and information are based on certain key expectations and assumptions made by the management of the Company. As a result, there can be no assurance that such plans will be completed as proposed or at all. Such forward-looking statements are based on a number of assumptions of management, including, without limitation, that the Company will complete the Consolidation; that the Company will receive the necessary approvals to complete the Consolidation; that the number of Subordinate Voting Shares outstanding following the Consolidation will be consistent with the number set out herein; and that the treatment of fractional shares will align with management's current expectations. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward–looking statements and information since no assurance can be given that they will prove to be correct. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward–looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to complete the Consolidation on the effective date, or at all; the number of post-Consolidation Subordinate Voting Shares may be different from the number set out herein and other risks detailed from time to time in the filings made by the Company in accordance with securities regulations. Accordingly, readers should not place undue reliance on the forward–looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward–looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward–looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Boston Globe
a day ago
- Boston Globe
For Boston's budding biotechs, an uncertain future amid funding cuts
Early stage startups, operating without much financial cushion, are feeling the impact sooner than better-established companies. Advertisement Dépis, and many entrepreneurs like him, are looking for ways to get their science funded. For example, LabCentral, a biotech startup incubator, has a program that allows big pharmaceutical companies to invest in cutting-edge science without making long-term commitments. Pharma companies cover the costs of lab space for individual scientists for a year, providing an easy exit if the research doesn't prove promising. In its recent five-year strategic plan, the Massachusetts Biotechnology Council pitched the idea of a seed fund to support companies that graduate from the trade group's incubator program. Discussions are underway with MassBio's partners such as LabCentral and the Massachusetts Life Sciences Center, a quasi-public state agency. Advertisement 'What's happened this year just validated our plans,' said MassBio CEO Kendalle Burlin O'Connell. 'We knew that we needed to support these early stage companies. We really, really feel it's imperative for Massachusetts to be an entrepreneur, founder-centric ecosystem.' Dépis — who is researching techniques to better deliver drugs to treat immune diseases — says such support is sorely needed. Earlier this year, he applied for a federal Small Business Innovation Research grant; then the government employee responsible for his application was laid off. Two weeks later, the employee was reinstated, but Dépis's application remains in limbo. 'I'm in a position where time is critical,' Dépis said. 'For me that translates into a higher chance to not have the funding in time that I need to survive.' And Dépis is not alone. Before the post-COVID biotech slump, companies accepted at LabCentral could typically secure funding and move into the space in a few weeks. Now, startups are taking six months to a year to move in — if they move in at all, said LabCentral CEO Maggie O'Toole. Startups at LabCentral are staying longer, unable to raise the money needed to grow their companies and expand into their own facilities, O'Toole said. The average length of tenancy doubled to about 36 months from 18 months, Some startups, affected by the Trump administration's grant cuts, have had to give up their LabCentral benches because they can't pay the rent. 'It was nothing to do with the promise of their science,' O'Toole said. 'They had received [approval for] funding that never came through.' Advertisement Robert Coughlin, a managing director at the commercial real estate firm JLL and former MassBio CEO, said the biotech industry is going through a downturn reminiscent of the Great Recession of 2008. Layoffs have spread across the sector. Earlier this month, Boston-based Vertex Pharmaceuticals said it would Moderna, the Cambridge biotech that soared with the success of its COVID vaccine, has gone through recent layoffs. In 2024, employment across Massachusetts' life sciences sector stagnated for the first time in more than 10 years, according to a report from the Massachusetts Biotechnology Education Foundation. Boston's commercial real estate sector has been hurt by the biotech slump. The vacancy rate for lab space has reached 32 percent, the highest among major metropolitan areas, according to JLL's most recent US Life Sciences Property Report. While conditions seem dismal, Coughlin said, he noticed a sense of optimism at the BIO conference. The annual convention not only attracted big crowds from established biotech centers, but also representatives from states and countries looking to invest in and build their own life sciences sectors. 'People want to get together,' Coughlin said. 'They want to collaborate, they want to talk about these challenges.' Marin Wolf can be reached at
Yahoo
a day ago
- Yahoo
Drone makers battle for air dominance with 'wingman' aircraft
By Joe Brock PARIS (Reuters) -Defence heavyweights and emerging military tech firms used the Paris Airshow to showcase cutting-edge drones known as "wingmen" - uncrewed aircraft designed to fly alongside next-generation fighter jets and reshape the future of air combat. The Paris show, the biggest aerospace and defence gathering in the world, featured a record number of drones, reflecting their rising importance after proving highly effective in the Ukraine war and as the U.S. prepares for a potential conflict with China in the Pacific. In April last year, the U.S. Air Force selected Anduril and General Atomics to develop the first fleet of drone wingmen, which are designed to fly alongside manned fighter jets and are officially known as Collaborative Combat Aircraft (CCA). California-based Anduril, which has already supplied small drones to Ukraine and was making its debut at the air show, displayed a model of its 17-foot Fury drone - planned for production in 2027 as part of the U.S. Air Force's CCA programme. "We're moving extremely fast," Jason Levin, Anduril's senior vice president of engineering, told Reuters. "The aircraft is very capable. We can't go into specifics here, but it performs the mission like a fighter." Levin said Anduril had raised $2.5 billion to build a 5-million-square-foot production facility in Ohio, with construction set to begin next year. In March, Anduril signed a 30-million-pound ($38 million) deal with Britain to supply its compact Altius drone to Ukraine. The drone can be launched from the ground or air and is capable of conducting strikes, serving as a decoy or for cyber warfare. Larger drones like Fury are part of the U.S. CCA programme, which aims to field around 1,000 autonomous drones capable of conducting surveillance, electronic warfare and strike operations alongside piloted fighter jets - such as Lockheed Martin's F-35 and the next-generation F-47, which Boeing was tapped to build following its selection by the Air Force in March. General Atomics showed off a model of its YFQ-42A drone at the show, which is its equivalent of the Fury, with both designed for potential use in the Pacific if China invaded democratically-ruled Taiwan. Last week, Boeing demonstrated the potential of drones operating in coordination with human pilots during a groundbreaking test with the Royal Australian Air Force, the U.S. aerospace giant announced at the air show. In the trial, two of Boeing's Ghost Bat drones flew alongside an E-7A Wedgetail surveillance aircraft, with a human operator remotely controlling the uncrewed systems to carry out a mission against an airborne target, the company said. "The Ghost Bat has the potential to turn a single fighter jet into a fighting team, with advanced sensors that are like hundreds of eyes in the sky," Australian Minister for Defence Industry Pat Conroy said in a statement. European defence firms are also advancing wingman drone initiatives, including Sweden's Saab and a trilateral partnership between Dassault Aviation, Airbus, and Indra Sistemas under the Future Combat Air System. The programme aims to integrate autonomous drones with manned fighter jets. Turkey's Baykar displayed two of its drone models at the show for the first time - the high-altitude, heavy lift Akinci and the TB3, which has foldable wings and can take off or land on short-runway aircraft carriers. On Monday, Baykar and Italian defence and aerospace group Leonardo formally launched a joint venture for unmanned systems. Germany's Rheinmetall announced at the show that it would partner with Anduril to build versions of Fury and Barracuda - a cruise missile-style drone - for European markets. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
